Brief: Aptinyx Reports Positive Data From Phase 2 Study of NYX-783 For PTSD

Aptinyx

19/10/2020 21:46

Oct 19 (Reuters) - Aptinyx Inc  APTX.O :
    * APTINYX REPORTS POSITIVE, STATISTICALLY SIGNIFICANT,
TOP-LINE
DATA FROM PHASE 2 STUDY OF NYX-783 IN PATIENTS WITH
POST-TRAUMATIC STRESS DISORDER
    * APTINYX INC - DATA SUPPORT DISCUSSION WITH FDA AND
ADVANCEMENT
INTO PIVOTAL STUDY
    * APTINYX INC - CLINICALLY MEANINGFUL IMPROVEMENT FROM
BASELINE ON
CAPS-5 TOTAL SCORE OBSERVED IN 50 MG DOSE ARM
    * APTINYX INC - OBSERVED SAFETY AND TOLERABILITY SIMILAR TO
PLACEBO
    * APTINYX INC - COMPANY EXPECTS TO INITIATE A PIVOTAL STUDY
IN
2021 FOR  NYX-783

Source text for Eikon:  ID:nBwc2lh2Pa 
Further company coverage:  APTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))